Hongyin Guo1, Qian Xiao1. 1. Department of Pharmacy, People's Hospital of Wu Qing TianJin 301700, China.
Abstract
OBJECTIVES: This study sought to determine the current effectiveness and safety of spironolactone for resistant hypertension. METHODS: Pubmed, EMBASE and Cochrane databases were searched to identify studies that used spironolactone as add-on treatment in resistant hypertension patients. The major outcome is reduction of blood pressure. RESULTS: Three randomized controlled trials, 5 observational study without control group have been identified. At follow-up review, there was a reduction in mean systolic and diastolic blood pressure (BP) respectively, of -20.56 mmHg (95% confidence interval [CI]: -36.47 to -4.65 mmHg) and -6.04 mm Hg (95% CI: -10.24 to -1.85 mm Hg) in controlled study. In uncontrolled studies, at 6-month follow-up, systolic and diastolic BP were reduced -20.73 mm Hg (95% CI: -25.62 to -15.83 mm Hg) and -8.94 mm Hg (95% CI: -10.82 to -7.05 mm Hg, respectively. CONCLUSION: Spironolactone resulted in the reduction of mean BP in patients with resistant hypertension. The sustained efficacy and safety of spironolactone need to further confirm by large randomized controlled trials with long-term follow-up.
OBJECTIVES: This study sought to determine the current effectiveness and safety of spironolactone for resistant hypertension. METHODS: Pubmed, EMBASE and Cochrane databases were searched to identify studies that used spironolactone as add-on treatment in resistant hypertensionpatients. The major outcome is reduction of blood pressure. RESULTS: Three randomized controlled trials, 5 observational study without control group have been identified. At follow-up review, there was a reduction in mean systolic and diastolic blood pressure (BP) respectively, of -20.56 mmHg (95% confidence interval [CI]: -36.47 to -4.65 mmHg) and -6.04 mm Hg (95% CI: -10.24 to -1.85 mm Hg) in controlled study. In uncontrolled studies, at 6-month follow-up, systolic and diastolic BP were reduced -20.73 mm Hg (95% CI: -25.62 to -15.83 mm Hg) and -8.94 mm Hg (95% CI: -10.82 to -7.05 mm Hg, respectively. CONCLUSION:Spironolactone resulted in the reduction of mean BP in patients with resistant hypertension. The sustained efficacy and safety of spironolactone need to further confirm by large randomized controlled trials with long-term follow-up.
Entities:
Keywords:
Spironolactone; meta analysis; resistant hypertension
Authors: William C Cushman; Charles E Ford; Jeffrey A Cutler; Karen L Margolis; Barry R Davis; Richard H Grimm; Henry R Black; Bruce P Hamilton; Joanne Holland; Chuke Nwachuku; Vasilios Papademetriou; Jeffery Probstfield; Jackson T Wright; Michael H Alderman; Robert J Weiss; Linda Piller; Judy Bettencourt; Sandra M Walsh Journal: J Clin Hypertens (Greenwich) Date: 2002 Nov-Dec Impact factor: 3.738
Authors: Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; William B White; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourciere; James Muller; Peter Sleight; Michael A Weber; Gordon Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders Journal: JAMA Date: 2003 Apr 23-30 Impact factor: 56.272
Authors: Jan Václavík; Richard Sedlák; Martin Plachy; Karel Navrátil; Jirí Plásek; Jirí Jarkovsky; Tomás Václavík; Roman Husár; Eva Kociánová; Milos Táborsky Journal: Hypertension Date: 2011-05-02 Impact factor: 10.190
Authors: David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey Journal: Hypertension Date: 2008-04-07 Impact factor: 10.190
Authors: Tatiana M Ripp; Victor F Mordovin; Stanislav E Pekarskiy; Tamara R Ryabova; Marina V Zlobina; Andrei E Baev; Yana Anfinogenova; Sergey V Popov Journal: Curr Hypertens Rep Date: 2015-12 Impact factor: 5.369
Authors: Rajiv Agarwal; Patrick Rossignol; Dahlia Garza; Martha R Mayo; Suzette Warren; Susan Arthur; Alain Romero; William B White; Bryan Williams Journal: Am J Nephrol Date: 2018-09-03 Impact factor: 3.754
Authors: Peter Makai; Joanna IntHout; Jaap Deinum; Kevin Jenniskens; Gert Jan van der Wilt Journal: J Gen Intern Med Date: 2017-03-08 Impact factor: 5.128